• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Does reimportation reduce price differences for prescription drugs? Lessons from the European Union.药品再进口是否会缩小处方药的价格差异?来自欧盟的经验教训。
Health Serv Res. 2008 Aug;43(4):1308-24. doi: 10.1111/j.1475-6773.2008.00838.x. Epub 2008 Mar 12.
2
The economics of parallel trade.平行贸易的经济学
Pharmacoeconomics. 1998 Mar;13(3):293-304. doi: 10.2165/00019053-199813030-00004.
3
Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect evidence from lower-income European countries.外部价格参考和平行贸易对药品支出的影响:来自低收入欧洲国家的间接证据。
Health Policy Plan. 2017 Apr 1;32(3):349-358. doi: 10.1093/heapol/czw133.
4
Parallel imports and the pricing of pharmaceutical products: evidence from the European Union.药品的平行进口与定价:来自欧盟的证据
J Health Econ. 2004 Sep;23(5):1035-57. doi: 10.1016/j.jhealeco.2004.03.005.
5
Impact of parallel trade on pharmaceutical firm's profits: rise or fall?平行贸易对制药公司利润的影响:上升还是下降?
Eur J Health Econ. 2013 Apr;14(2):345-55. doi: 10.1007/s10198-012-0380-0.
6
Assessing the impact of global price interdependencies.评估全球价格相互依存关系的影响。
Pharmacoeconomics. 2008;26(8):649-59. doi: 10.2165/00019053-200826080-00003.
7
The pros and cons of a single 'Euro-price' for drugs.药品单一“欧元价格”的利弊。
Pharmacoeconomics. 1998 Mar;13(3):271-6. doi: 10.2165/00019053-199813030-00001.
8
International trade and determinants of price differentials of insulin medicine.胰岛素药物的国际贸易与价格差异的决定因素
Health Policy Plan. 2017 Feb;32(1):1-10. doi: 10.1093/heapol/czw085. Epub 2016 Jun 26.
9
The hidden cost of low prices: limited access to new drugs in India.低价的隐藏成本:印度新药可及性受限。
Health Aff (Millwood). 2014 Sep;33(9):1567-75. doi: 10.1377/hlthaff.2013.1307.
10
Pharmaceutical pricing, price controls, and their effects on pharmaceutical sales and research and development expenditures in the European Union.欧盟的药品定价、价格管制及其对药品销售以及研发支出的影响。
Clin Ther. 2004 Aug;26(8):1327-40; discussion 1326. doi: 10.1016/s0149-2918(04)80209-1.

引用本文的文献

1
What is the impact of intellectual property rules on access to medicines? A systematic review.知识产权规则对药品可及性有何影响?一项系统综述。
Global Health. 2022 Apr 15;18(1):40. doi: 10.1186/s12992-022-00826-4.
2
Hemolytic disease of the fetus and newborn due to Rh(D) incompatibility: A preventable disease that still produces significant morbidity and mortality in children.由 Rh(D) 不相容引起的胎儿和新生儿溶血病:一种可预防的疾病,但仍会导致儿童出现严重的发病率和死亡率。
PLoS One. 2020 Jul 20;15(7):e0235807. doi: 10.1371/journal.pone.0235807. eCollection 2020.
3
Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe.中东欧的肿瘤药物支出与癌症病死率与发病率比
Oncologist. 2019 Jan;24(1):e30-e37. doi: 10.1634/theoncologist.2018-0093. Epub 2018 Sep 4.
4
Overview of external reference pricing systems in Europe.欧洲外部参考定价系统概述。
J Mark Access Health Policy. 2015 Sep 10;3. doi: 10.3402/jmahp.v3.27675. eCollection 2015.

本文引用的文献

1
Prices and availability of biopharmaceuticals: an international comparison.生物制药的价格与可及性:一项国际比较
Health Aff (Millwood). 2006 Sep-Oct;25(5):1353-62. doi: 10.1377/hlthaff.25.5.1353.
2
Developing drugs for developing countries.为发展中国家研发药物。
Health Aff (Millwood). 2006 Mar-Apr;25(2):313-24. doi: 10.1377/hlthaff.25.2.313.
3
Prices and availability of pharmaceuticals: evidence from nine countries.药品价格与可及性:来自九个国家的证据
Health Aff (Millwood). 2003 Jul-Dec;Suppl Web Exclusives:W3-521-36. doi: 10.1377/hlthaff.w3.521.
4
Parallel imports and the pricing of pharmaceutical products: evidence from the European Union.药品的平行进口与定价:来自欧盟的证据
J Health Econ. 2004 Sep;23(5):1035-57. doi: 10.1016/j.jhealeco.2004.03.005.
5
The effect of incentive-based formularies on prescription-drug utilization and spending.基于激励措施的药品处方集对处方药使用及支出的影响。
N Engl J Med. 2003 Dec 4;349(23):2224-32. doi: 10.1056/NEJMsa030954.
6
Employer drug benefit plans and spending on prescription drugs.雇主药物福利计划与处方药支出
JAMA. 2002 Oct 9;288(14):1733-9. doi: 10.1001/jama.288.14.1733.
7
Cross-national price differences for pharmaceuticals: how large, and why?药品的跨国价格差异:有多大,原因何在?
J Health Econ. 2000 Mar;19(2):159-95. doi: 10.1016/s0167-6296(99)00039-9.

药品再进口是否会缩小处方药的价格差异?来自欧盟的经验教训。

Does reimportation reduce price differences for prescription drugs? Lessons from the European Union.

作者信息

Kyle Margaret K, Allsbrook Jennifer S, Schulman Kevin A

机构信息

The Fucqua School of Business, Duke University, Durham, NC, USA.

出版信息

Health Serv Res. 2008 Aug;43(4):1308-24. doi: 10.1111/j.1475-6773.2008.00838.x. Epub 2008 Mar 12.

DOI:10.1111/j.1475-6773.2008.00838.x
PMID:18355258
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2517281/
Abstract

OBJECTIVE

To examine the effect of parallel trade on patterns of price dispersion for prescription drugs in the European Union.

DATA SOURCES

Longitudinal data from an IMS Midas database of prices and units sold for drugs in 36 categories in 30 countries from 1993 through 2004.

STUDY DESIGN

The main outcome measures were mean price differentials and other measures of price dispersion within European Union countries compared with within non-European Union countries.

DATA COLLECTION/EXTRACTION METHODS: We identified drugs subject to parallel trade using information provided by IMS and by checking membership lists of parallel import trade associations and lists of approved parallel imports.

PRINCIPAL FINDINGS

Parallel trade was not associated with substantial reductions in price dispersion in European Union countries. In descriptive and regression analyses, about half of the price differentials exceeded 50 percent in both European Union and non-European Union countries over time, and price distributions among European Union countries did not show a dramatic change concurrent with the adoption of parallel trade. In regression analysis, we found that although price differentials decreased after 1995 in most countries, they decreased less in the European Union than elsewhere.

CONCLUSIONS

Parallel trade for prescription drugs does not automatically reduce international price differences. Future research should explore how other regulatory schemes might lead to different results elsewhere.

摘要

目的

研究平行贸易对欧盟处方药价格离散模式的影响。

数据来源

1993年至2004年期间,来自IMS Midas数据库的关于30个国家36类药品价格和销售数量的纵向数据。

研究设计

主要观察指标为欧盟国家内部与非欧盟国家内部的平均价格差异以及其他价格离散指标。

数据收集/提取方法:我们利用IMS提供的信息,并通过核查平行进口贸易协会的成员名单和获批平行进口药品清单,确定了涉及平行贸易的药品。

主要发现

平行贸易与欧盟国家价格离散的大幅降低并无关联。在描述性分析和回归分析中,随着时间推移,欧盟国家和非欧盟国家约一半的价格差异超过了50%,且欧盟国家之间的价格分布在采用平行贸易后并未出现显著变化。在回归分析中,我们发现尽管大多数国家的价格差异在1995年后有所下降,但欧盟国家下降的幅度小于其他地区。

结论

处方药的平行贸易不会自动缩小国际价格差异。未来的研究应探讨其他监管方案在其他地区可能如何导致不同的结果。